Your session is about to expire
← Back to Search
Wnt Pathway Inhibitor
JNJ-64251330 for Adenomatous Polyposis
Phase 1
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 32 weeks
Awards & highlights
Study Summary
This trial will test if a new drug can help reduce the size of polyps in people with a genetic disorder that causes them to grow.
Eligible Conditions
- Familial Adenomatous Polyposis (FAP)
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 32 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 32 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24
Percentage Change from Baseline in Colorectal Polyp Burden for all Polyps at Week 24
Secondary outcome measures
Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Polyposis Stage (with and Without Colon)
Change in Spigelman Stage Score
Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps
+12 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: JNJ-64251330Experimental Treatment1 Intervention
Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-64251330
2021
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Janssen Research & Development, LLCLead Sponsor
978 Previous Clinical Trials
6,385,027 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
747 Previous Clinical Trials
3,960,605 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger